Rangaswamy Govindarajan, MD | Authors


11 S 8TH ST


Irinotecan/Thalidomide in Metastatic Colorectal Cancer

April 01, 2002

The prognosis for patients with metastatic colorectal cancer is poor. Use of irinotecan (CPT-11, Camptosar) results in modest response rates of approximately 20% in refractory patients diagnosed with this advanced stage of disease and offers a side-effect profile that improves on that of previous standard treatments.

Current Status of Thalidomide in the Treatment of Cancer

July 01, 2001

Dr. Rajkumar has written an excellent overview of the current status of thalidomide (Thalomid) in the treatment of cancer. There is a constant demand for novel therapeutic strategies as alternative or complementary options to the existing armamentarium of chemotherapeutic agents for various malignant disorders.

Irinotecan and Thalidomide in Metastatic Colorectal Cancer

December 02, 2000

Fifteen patients with metastatic colorectal cancer were treated with irinotecan (CPT-11, Camptosar) at 300 to 350 mg/m2 every 21 days and thalidomide (Thalomid) at 400 mg/d. Of the 15 patients, 11 were in a pilot study and 4